Wisdom Financial News App, Morimatsu International (02155) announced that as of September 30, 2024, shareholders of Morimatsu Pharmaceuticals (its wholly-owned subsidiary) have approved Morimatsu Pharmaceuticals' adoption of a stock-based incentive plan. According to the stock-based incentive plan, Morimatsu Pharmaceuticals intends to grant a total of RMB 12.86871 million in new registered capital by way of investment to incentive recipients, accounting for approximately 14.91% of its total registered capital after the investment. After the investment, the incentive recipients will directly hold shares of Morimatsu Pharmaceuticals.

On the date of this announcement, the company holds 100% equity of Morimatsu Pharmaceuticals directly and indirectly. Assuming that the incentive recipients complete the investment according to the stock-based incentive plan; and from the announcement date to the completion of the investment, there are no other changes in the total registered capital of Morimatsu Pharmaceuticals and the company's equity in Morimatsu Pharmaceuticals, the company's equity in Morimatsu Pharmaceuticals will decrease from 100% to approximately 85.09% after the investment.